Company intelligence / Profile preview

AV7 Ltd

Not specified, Not specified, United Kingdomav7.org ↗

Ownership: Private
Development stage: Other

Overview

AV7 Ltd has completed a Phase 1 clinical trial for its lead candidate K1‑70, a thyroid stimulating hormone receptor antagonist monoclonal antibody. The study evaluated safety and tolerability in patients with Graves’ disease. No further clinical results are publicly available at this time.[1]

Therapeutic areas: OncologyEndocrinology
Modalities: Monoclonal antibodies (mAbs) (K1-70 is a TSH receptor antagonist antibody)[1]
Industry: Biotech

Drug pipeline

2 assets

K1-70

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on AV7 Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV7 Ltd.

Explore the full profile